Veeva Systems Q1 2026 slides: Revenue jumps 17% as operating margins hit 46%

Veeva Systems (VEEV) reported strong Q1 fiscal year 2026 results, with total revenue up 17% year-over-year to $759 million and subscription revenue increasing 19% to $635 million, driving an 11.04% surge in after-hours trading. Non-GAAP operating income reached $350 million, yielding a 46.1% operating margin, significantly improved from 40.1% in Q1 2025. The company projects FY26 revenue between $3.09 and $3.1 billion, reflecting approximately 13% growth, and reaffirmed its target of $6 billion in revenue by 2030, requiring a 14% compound annual growth rate.

Analysis

Veeva Systems (NYSE:VEEV) delivered a strong Q1 fiscal year 2026, with total revenues increasing 17% year-over-year to $759 million, primarily driven by a 19% surge in subscription revenue to $635 million, which now constitutes approximately 84% of total revenue. This performance, exceeding expectations, resulted in an 11.04% after-hours stock increase to $261 and highlighted exceptional profitability, with non-GAAP operating margins expanding significantly to 46.1% from 40.1% in the prior year's quarter, marking the highest in recent quarters. The company's FY26 guidance projects continued momentum, with anticipated total revenue of $3.09-$3.10 billion (approximately 13% growth) and a robust non-GAAP operating margin around 44%, aligning with its long-term target of $6 billion in revenue by 2030. Normalized billings, a key forward indicator, are projected to grow approximately 12% to $3.32 billion in FY26, underscoring sustained demand. While a recent change in Termination for Convenience (TFC) rights, effective February 1, 2023, impacts revenue recognition timing for some multi-year deals, Veeva has clarified this does not affect underlying cash flows, billings, or total deal revenue, and the company continues to benefit from the life sciences sector's noted resilience and strategic investments in areas like AI-driven products.

Key Decisions for Investors

• Investors should recognize Veeva's strong Q1 FY26 performance and positive FY26 guidance, including projected 13% total revenue growth and a 44% non-GAAP operating margin, as continued validation of its business model and market leadership in the life sciences cloud sector.
• Consider the company's robust operating cash flow, which is guided to approximately $1,210 million for FY26, and significant normalized billings growth as key indicators of future financial health and its ability to fund growth towards its $6 billion revenue target by 2030.
• While fundamental performance is robust, investors should carefully monitor valuation levels following the significant stock appreciation and consider external perspectives on fair value, alongside tracking the execution and impact of strategic initiatives, such as AI product development, on sustained long-term growth.